Patents by Inventor Philip M. Toleikis

Philip M. Toleikis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9353218
    Abstract: Multifunctional compounds are provided that readily crosslink in situ to provide crosslinked biomaterials. The multifunctional compounds contain a single component having at least three reactive functional groups thereon, with the functional groups selected so as to be non-reactive in an initial environment and inter-reactive in a modified environment. Reaction of a plurality of the multifunctional compounds results in a three-dimensional crosslinked matrix. In one embodiment, a first functional group is nucleophilic, a second functional group is electrophilic, and at least one additional functional group is nucleophilic or electrophilic. Methods for preparing and using the multifunctional compounds, and kits including the multifunctional compounds are also provided. Exemplary uses for the multifunctional compounds include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: May 31, 2016
    Inventors: George Y. Daniloff, Michael Huy Ngo, Olof Mikael Trollsas, David M. Gravett, Philip M. Toleikis
  • Patent number: 9326934
    Abstract: Compositions are disclosed that afford drug delivery from two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired along with drug delivery. For example, the compositions are useful as tissue sealants, in promoting hemostasis, in effecting tissue adhesion, in providing tissue augmentation, and in the prevention of surgical adhesions.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: May 3, 2016
    Inventors: David M. Gravett, Aniko Takacs-Cox, Philip M. Toleikis, Arpita Maiti, Leanne Embree
  • Publication number: 20140328891
    Abstract: Medical implants are provided which release a fluoropyrimidine or an analog thereof, thereby inhibiting or reducing the incidence of infection associated with the implant.
    Type: Application
    Filed: July 17, 2014
    Publication date: November 6, 2014
    Inventors: William L. Hunter, David M. Gravett, Philip M. Toleikis, Richard T. Liggins, Troy A.E. Loss
  • Publication number: 20130296367
    Abstract: This application describes compositions of receptor inhibitors, including antipsychotic agents, for example haloperidol, and methods of use for alleviating clinical depression, improving cognition and/or treating other syndromes, conditions or diseases for which anti-depressant agents are prescribed. Furthermore, this application describes compositions and methods to induce supersensitivity in dopamine D2 and other receptors involved in depression and/or cognition as a means of alleviating clinical depression or improving cognition.
    Type: Application
    Filed: July 2, 2013
    Publication date: November 7, 2013
    Inventors: Philip Seeman, Philip M. Toleikis
  • Publication number: 20130289235
    Abstract: Multifunctional compounds are provided that readily crosslink in situ to provide crosslinked biomaterials. The multifunctional compounds contain a single component having at least three reactive functional groups thereon, with the functional groups selected so as to be non-reactive in an initial environment and inter-reactive in a modified environment. Reaction of a plurality of the multifunctional compounds results in a three-dimensional crosslinked matrix. In one embodiment, a first functional group is nucleophilic, a second functional group is electrophilic, and at least one additional functional group is nucleophilic or electrophilic. Methods for preparing and using the multifunctional compounds, and kits including the multifunctional compounds are also provided. Exemplary uses for the multifunctional compounds include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.
    Type: Application
    Filed: June 14, 2013
    Publication date: October 31, 2013
    Inventors: George Y. Daniloff, Michael Huy Ngo, Olof Mikael Trollsas, David M. Gravett, Philip M. Toleikis
  • Patent number: 8486437
    Abstract: Multifunctional compounds are provided that readily crosslink in situ to provide crosslinked biomaterials. The multifunctional compounds contain a single component having at least three reactive functional groups thereon, with the functional groups selected so as to be non-reactive in an initial environment and inter-reactive in a modified environment. Reaction of a plurality of the multifunctional compounds results in a three-dimensional crosslinked matrix. In one embodiment, a first functional group is nucleophilic, a second functional group is electrophilic, and at least one additional functional group is nucleophilic or electrophilic. Methods for preparing and using the multifunctional compounds, and kits including the multifunctional compounds are also provided. Exemplary uses for the multifunctional compounds include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: July 16, 2013
    Assignee: Angiotech Pharmaceuticals (US), Inc.
    Inventors: George Y. Daniloff, Michael Huy Ngo, Olof Mikael Trollsas, David M. Gravett, Philip M. Toleikis
  • Patent number: 8481073
    Abstract: Methods of preventing adhesion between issues are provided that utilizes in situ crosslinked biomaterials. The biomaterial contains at least the crosslinked product of two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked compositions include preventing adhesions following surgery or injury, and preventing scar tissue formation.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: July 9, 2013
    Assignee: AngioDevice International GmbH
    Inventors: George Y. Daniloff, Louis C. Sehl, Olof Mikael Trollsas, Jacqueline A. Schroeder, David M. Gravett, Philip M. Toleikis
  • Patent number: 8460708
    Abstract: Kits comprising dry power compositions are provided that readily crosslink in situ to provide crosslinked biomaterials. The dry powder composition contains at least two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked biomaterials include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: June 11, 2013
    Assignee: AngioDevice International GmbH
    Inventors: George Y. Daniloff, Louis C. Sehl, Olof Mikael Trollsas, Jacqueline A. Schroeder, David M. Gravett, Philip M. Toleikis
  • Patent number: 8425927
    Abstract: Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant.
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: April 23, 2013
    Assignee: Angiotech International AG
    Inventors: William L. Hunter, David M. Gravett, Philip M. Toleikis, Richard T. Liggins, Troy A. E. Loss
  • Patent number: 8372420
    Abstract: Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant.
    Type: Grant
    Filed: September 3, 2009
    Date of Patent: February 12, 2013
    Assignee: Angiotech International AG
    Inventors: William L. Hunter, David M. Gravett, Philip M. Toleikis, Richard T. Liggins, Troy A. E. Loss
  • Publication number: 20130012683
    Abstract: Multifunctional compounds are provided that readily crosslink in situ to provide crosslinked biomaterials. The multifunctional compounds contain a single component having at least three reactive functional groups thereon, with the functional groups selected so as to be non-reactive in an initial environment and inter-reactive in a modified environment. Reaction of a plurality of the multifunctional compounds results in a three-dimensional crosslinked matrix. In one embodiment, a first functional group is nucleophilic, a second functional group is electrophilic, and at least one additional functional group is nucleophilic or electrophilic. Methods for preparing and using the multifunctional compounds, and kits including the multifunctional compounds are also provided. Exemplary uses for the multifunctional compounds include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicant: ANGIOTECH PHARMACEUTICALS (US), INC.
    Inventors: George Y. Daniloff, Michael Huy Ngo, Olof Mikael Trollsas, David M. Gravett, Philip M. Toleikis
  • Patent number: 8313760
    Abstract: Medical implants are provided which release a fluoropyrimidine or an analog thereof, thereby inhibiting or reducing the incidence of infection associated with the implant.
    Type: Grant
    Filed: April 22, 2008
    Date of Patent: November 20, 2012
    Assignee: Angiotech International AG
    Inventors: William L Hunter, David M Gravett, Philip M Toleikis, Richard T Liggins, Troy A. E. Loss
  • Patent number: 8303973
    Abstract: Multifunctional compounds are provided that readily crosslink in situ to provide crosslinked biomaterials. The multifunctional compounds contain a single component having at least three reactive functional groups thereon, with the functional groups selected so as to be non-reactive in an initial environment and inter-reactive in a modified environment. Reaction of a plurality of the multifunctional compounds results in a three-dimensional crosslinked matrix. In one embodiment, a first functional group is nucleophilic, a second functional group is electrophilic, and at least one additional functional group is nucleophilic or electrophilic. Methods for preparing and using the multifunctional compounds, and kits including the multifunctional compounds are also provided. Exemplary uses for the multifunctional compounds include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.
    Type: Grant
    Filed: September 19, 2005
    Date of Patent: November 6, 2012
    Assignee: Angiotech Pharmaceuticals (US), Inc.
    Inventors: George Y. Daniloff, Michael Huy Ngo, Olof Mikael Trollsas, David M. Gravett, Philip M. Toleikis
  • Publication number: 20120252905
    Abstract: Compositions are disclosed that afford drug delivery from two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired along with drug delivery. For example, the compositions are useful as tissue sealants, in promoting hemostasis, in effecting tissue adhesion, in providing tissue augmentation, and in the prevention of surgical adhesions.
    Type: Application
    Filed: May 1, 2012
    Publication date: October 4, 2012
    Inventors: David M. Gravett, Aniko Takacs-Cox, Philip M. Toleikis, Arpita Maiti, Leanne Embree
  • Publication number: 20120052040
    Abstract: Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.
    Type: Application
    Filed: March 22, 2011
    Publication date: March 1, 2012
    Applicant: Angiotech International AG
    Inventors: William L. Hunter, Philip M. Toleikis, David M. Gravelt, Arpita Maiti, Richard T. Liggins, Aniko Takacs-Cox, Rui Avelar, Troy A.E. Loss, Dechi Guan, Kaiyue Wang
  • Publication number: 20120039980
    Abstract: Methods of preventing adhesion between issues are provided that utilizes in situ crosslinked biomaterials. The biomaterial contains at least the crosslinked product of two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked compositions include preventing adhesions following surgery or injury, and preventing scar tissue formation.
    Type: Application
    Filed: October 24, 2011
    Publication date: February 16, 2012
    Inventors: George Y. Daniloff, Louis C. Sehl, Olof Mikael Trollsas, Jacqueline Schroeder, David M. Gravett, Philip M. Toleikis
  • Publication number: 20120041481
    Abstract: Kits comprising dry power compositions are provided that readily crosslink in situ to provide crosslinked biomaterials. The dry powder composition contains at least two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked biomaterials include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.
    Type: Application
    Filed: October 24, 2011
    Publication date: February 16, 2012
    Applicant: AngioDevice International GmbH
    Inventors: George Y. Daniloff, Louis C. Sehl, Olof Mikael Trollsas, Jacqueline Schroeder, David M. Gravett, Philip M. Toleikis
  • Patent number: 8067031
    Abstract: Crosslinkable compositions are provided that readily crosslink in situ to provide crosslinked biomaterials. The composition contains at least two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. In one embodiment, a first component has nucleophilic groups and a second component has electrophilic groups. Additional components may have nucleophilic or electrophilic groups. Methods for preparing and using the compositions are also provided as are kits for delivery of the compositions. Exemplary uses for the crosslinked compositions include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.
    Type: Grant
    Filed: April 28, 2005
    Date of Patent: November 29, 2011
    Assignee: AngioDevice International GmbH
    Inventors: George Y. Daniloff, Louis C. Sehl, Olof Mikael Trollsas, Jacqueline Schroeder, David M. Gravett, Philip M. Toleikis
  • Publication number: 20110264139
    Abstract: Sutures are used in combination with fibrosing agents to induce or stimulate fibrosis that between the sutures and the host tissues into which the sutures are inserted. Compositions and methods are described for use in lifting tissue, closing wound, and other applications.
    Type: Application
    Filed: April 12, 2011
    Publication date: October 27, 2011
    Applicant: Angiotech Pharmaceuticals, Inc.
    Inventors: William L. HUNTER, Rui Avelar, David Gravett, Philip M. Toleikis, Arpita Maiti
  • Patent number: H2260
    Abstract: Stents are used in combination with a paclitaxel derivative in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. Suitable implants include vascular stents, esophageal stents, tracheal or bronchial stents, gastrointestinal stents, genital-urinary stents, nasal and sinus stents, and ENT stents.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: July 5, 2011
    Assignee: Angiotech International AG
    Inventor: Philip M. Toleikis